Arrowhead Pharmaceuticals' stock plummeted 5.88% during intraday trading on Thursday, following the release of its first-quarter financial results.
The biopharmaceutical company reported revenue of $264.033 million for the quarter, falling short of the IBES estimate of $270.1 million. This revenue miss occurred despite the company achieving a more than 100-fold increase in revenue compared to the same period last year.
Operating expenses for the quarter were reported at $223.224 million. While the company highlighted significant business developments including product approvals and a substantial upfront payment from Novartis, investors reacted negatively to the revenue shortfall against analyst expectations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.